Johnson & Johnson’s Janssen Biotech will partner with Fate Therapeutics to create cell-based cancer immunotherapies derived from induced pluripotent stem cells, through a collaboration that could generate more than $3 billion for the San Diego cellular immunotherapy developer. Janssen will bring to the partnership its proprietary antigen binding domains, with the aim of creating with Fate product candidates for up to four tumor associated antigens for blood and solid cancers.